title: Antibody-based therapeutics against components of the IGF system.
abstract: The insulin-like growth factor I (IGF-I) receptor (IGF-1R) is overexpressed in most human neoplasms tested so far. Many tumors in young patients produce high levels of the IGF-1R ligands, IGF-I and IGF-II. Given the complexity of the IGF signaling pathway, its complete inhibition may require combination therapies with antibodies targeting both IGF-1R and IGF-II.
authors.affiliation: Protein Interactions Group; FNLCF; NIH; Frederick, MD USA.
authors.forename: Yang
authors.initials: Y
authors.lastname: Feng
authors.forename: Dimiter S
authors.initials: DS
authors.lastname: Dimitrov